The TBI delays are maybe the only serious ongoing downer. OK the Perseis stuff-up was a pain but there seems to be a plan that's on track and has solid time lines.
2256 and Perseis, as the flagships, are about as low risk as you could ask for. Which is to say: look, it's a bio, of course it's a high risk investement, but within that spectrum, for me it's a respectably safe bet.
2591 and Motiva are clearly not as high up on the agenda, but if 2591 is effective for Parkie's and stroke victims, well that's a huge market too. (Maybe they should send some to Michael J. Fox?).
My verdict: no new disasters, dealing with the previous ones and gradually making progress.
NEU Price at posting:
2.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)